INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
14/07/2026
Voltar para busca
Dado oficial do USPTO
HYFC TECHNOLOGY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
14/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
28/02/2018
Data de registro
30/04/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/11/2025
Última transação
14/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
98
Localização do titular
KR
Examinador
EISNACH, MICHAEL PATRICK
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
Titulares e representantes
Titulares
Genexine, Inc.
Representantes
Diane J. Mason Drinker Biddle & Reath LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseasesfor the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
C71T
CANCELLED SECTION 71
14/11/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
28/11/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
30/04/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/05/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/09/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/08/2019
FIMP
FINAL DISPOSITION PROCESSED
24/08/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/07/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/05/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
30/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/02/2019
PUBO
PUBLISHED FOR OPPOSITION
12/02/2019
GPNX
NOTIFICATION PROCESSED BY IB
08/02/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/01/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
23/01/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/01/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/12/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/12/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/12/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/12/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/12/2018
RFNT
REFUSAL PROCESSED BY IB
14/07/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/06/2018
RFRR
REFUSAL PROCESSED BY MPU
28/06/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/06/2018
CNRT
NON-FINAL ACTION WRITTEN
19/06/2018
DOCK
ASSIGNED TO EXAMINER
12/06/2018
MAFR
APPLICATION FILING RECEIPT MAILED
05/06/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/06/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/05/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HYFC TECHNOLOGY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.